Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.72 |
| ▸ | NPC1 | O15118 | 7/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.60 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756247 | 0.87 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11092496 | 0.85 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15525711 | 0.82 | MTNR1B (0.55) | RAB9ANPC1SMN1; SMN2KMT2ATP53 | |
| SCHEMBL171952 | 0.81 | L3MBTL1 (0.61) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13713061 | 0.81 | EPHX2 (0.75) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18364900 | 0.81 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18364369 | 0.81 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6324843 | 0.79 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11875380 | 0.79 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17628550 | 0.79 | RAB9A (0.88) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | RAB9A 1353/4885NPC1 268/4885SMN1; SMN2 3760/4885 |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | DHX15, DDX5, DHX35 | RAB9A 3431/4885NPC1 2518/4885SMN1; SMN2 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.